News & Updates

COVID-19 vaccine acceptance is high in Singapore, but there are still a reluctant few who prevent the nation from getting a higher immunization coverage against the infection.

Greater concentrations of selenium appear to lower all-cause and heart disease mortality among individuals with type 2 diabetes (T2D), suggests a study.

Older diabetic patients with acute heart failure who undergo physical rehabilitation have worse baseline physical function but demonstrate similar clinically meaningful improvements from the intervention, results of the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial have shown. However, the benefit derived for frailty is lesser among those with diabetes.

In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.

Cardiac rehabilitation is standard for the treatment of heart failure (HF) and yields short-term prognostic benefits, a recent study has found. However, long-term benefits remain uncertain.

The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.